|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
SIMPLE MOVING AVERAGE
Trading: SELL @ $0.061
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Bionomics (ASX:BNO) currently has a confirmed downtrend. This means the SMA 15 day average has moved below the closing price confirming the short term trend following indicator. Currently, the return on SMA15 is -3.2%.
A simple moving average is formed by computing the average price of a security over a specific number of periods. Most moving averages are based on closing prices.
Calculation: Simple Moving Average:
1) SMA: n period sum / n;
PROFILE: Bionomics (BNO.AX)
Stock Exchange: ASX
Ticker Codes: | BNO.AX | ASX:BNO |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
|DCN Dacian Gold||0.55||23.6||6,024,943||-44.4||BEARISH|
|GTN GTN Resources||1.1||10||161,378||-1.2||BEARISH|
|LNG Liquefied Natural Gas||0.29||9.6||1,664,251||-0.5||BEARISH|
|TZN Terramin Australia||0.08||8.7||388,211||-2.1||BEARISH|
|SMX Sms Management & Technology||0.39||5.4||102,965||-0.6||BEARISH|
|FBR Fastbrick Robotics||0.08||4.2||978,830||-2.6||BEARISH|
|BBN Baby Bunting||2.18||3.8||510,542||-3.6||BEARISH|
|SXY Senex Energy||0.29||3.6||10,559,722||-3.6||BEARISH|